Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

ALGN Align Technology SEC Filings & Insider Trading Activity 2026

company
CIK 109714996 filings
S&P 500

ALGN at a glance

Align Technology (ALGN, SEC CIK 1097149) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Align Technology (ALGN) reported revenue of $4.0 billion (up 0.9% from FY2024) and net income of $410.4 million. Diluted EPS was $5.65.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Align Technology (ALGN) shares worth $3.8 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$4.0B
+0.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
36 funds
$3.8B · −2 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 5.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Section 232 investigation by U.S. Dept of Commerce into PPE/medical device imports directly threatens Align's Mexico-manufactured clear aligners shipped to U.S.
  • iTero HQ in Israel near Hamas conflict zone; Mexico manufacturing exposed to drug cartel/gang activity disrupting production and logistics
  • Heavy dependence on sole-source suppliers for specialized resin, rapid prototyping machines, and iTero optics components with no quick replacement path
  • Competitors integrating AI/ML into orthodontic workflows risk commoditizing Invisalign; DTC aligner companies bypassing doctor channel further erode pricing power
  • Revenue concentrated in Invisalign System as primary revenue driver; restructuring plans executed three consecutive fiscal years signal persistent operational instability

Management Discussion & Analysis

  • Revenue $4,035M, up 0.9% YoY ($+$36M); Clear Aligner +0.5% to $3,245M, Systems & Services +2.7% to $790M
  • Gross margin 67.2% vs 70.0%; operating margin 13.5% vs 15.2%; Clear Aligner margin 31.9% vs 35.4%; Systems & Services margin 38.8% vs 35.0%
  • Best segment: Systems & Services op margin 38.8% vs 35.0%; worst: Clear Aligner dragged by $77M accelerated depreciation and ASP decline 3.9% ($1,245 vs $1,295)
  • Operating cash flow $593M vs $738M YoY; capex $102M; buybacks $466M; $831M remaining under repurchase program; no dividends
  • Key risks: tariff volatility, macro uncertainty dampening discretionary spending, orthodontic starts down four consecutive years; FY2026 capex guided $125–$150M

Business Overview

  • Global med-device co: design/manufacture/market Invisalign clear aligners (~80% revenue), iTero scanners, and exocad CAD/CAM software via integrated Align Digital Platform
  • 2025 new launches: iTero Lumina Pro with NIRI technology (March), Align X-ray Insights AI-based caries detection in EU/UK (March), Invisalign MAOB for Class II teen patients (December)
  • Direct fabrication via Cubicure (acquired Jan 2024) scaling toward millions of 3D-printed devices/day; retainers and pre-fab attachments pilot releases planned 2026
  • Headcount ~20,290 as of Dec 31, 2025: down 3.1% YoY and 6.1% vs 2023, signaling ongoing workforce contraction despite product expansion
  • Invisalign holds only ~10% share of ~22M annual global orthodontic case starts: massive untapped market framing core growth narrative

AI summary of the ALGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: European Commission formal competition investigation announced June 29, 2026, covering Invisalign and iTero practices
  • Most material trade update: Section 301 duties on imports from 60 U.S. trade partners began July 24, 2026, without a fixed expiration date
  • Compliance risk: FDA Quality Management System Regulation became effective February 2, 2026, adding inspection and enforcement exposure
  • Near-term market risk: Intensifying competition, including AI-enabled dental technologies and lower-priced clear aligners
  • Financial risk: Foreign-currency fluctuations affecting international revenues, expenses, results of operations and cash flows

Management Discussion & Analysis

  • Revenue $1,014.8M, up 1.9% YoY from $995.7M
  • Clear Aligners best segment: $839.3M, up 4.2% YoY; Systems and Services $175.5M, down 7.6%
  • Operating margin 16.7% vs 9.7% YoY; gross margin 68.7% vs 64.2%
  • Cash $1,145M; operating cash flow $183M; capital expenditures $45M; share repurchases $201.2M year-to-date
  • Headwinds: tariffs, macroeconomic uncertainty, lower ASPs, unfavorable foreign exchange, UK VAT liability $43.1M

AI summary of the ALGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expands from 11 to 13 directors, adding Paul Clancy immediately and Ian Bell effective December 10, 2026
  • Both nominees expected to stand for shareholder election at the May 2027 annual meeting

Item EX-99.1: Item EX-99.1

  • Paul J. Clancy appointed director immediately, adding former Alexion and Biogen CFO expertise
  • Ian Bell joins December 10, 2026, bringing Alcon commercial, manufacturing, quality and regulatory experience
Filed Nov 6, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $270 million ASR with Goldman Sachs, funded upfront from Align’s $1.0 billion repurchase authorization
  • Approximately 1.44 million shares delivered initially, reducing shares outstanding and supporting per-share metrics

Item EX-99.1: Item EX-99.1

  • $270 million accelerated stock repurchase with Goldman Sachs, funded from cash on hand
  • Expected completion by December 29, 2026, with final shares tied to volume-weighted average price less discount
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • CEO succession: Jennifer L. Davis becomes President and CEO December 31, 2026, signaling a planned leadership transition
  • Davis joins as CEO-elect and director November 2, 2026, enabling nearly two months of overlap with Joseph Hogan

Item 7.01: Regulation FD Disclosure

  • Press release announces CEO succession plan, making leadership transition the key investor-relevant disclosure
  • Exhibit 99.1 contains the full announcement and details on related Item 5.02 matters

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jennifer L. Davis becomes CEO-elect November 2, 2026 and CEO December 31, 2026, succeeding retiring CEO Joseph Hogan
  • Davis brings 33 years of P&G leadership, including CEO of Health Care, supporting innovation and digital transformation priorities

AI summaries of ALGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALGN

Don't miss the next ALGN filing

  • Alerts as it files. A push when ALGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALGN, by share count.
  • Ask anything. An AI agent that reads every ALGN filing and answers with sources.

ALGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Clancy Paul JANov 17, 2026-
Blackford Quentin S.AAug 27, 2026-
Conroy Kevin TMMay 20, 2026-
LACOB JOSEPHMMay 20, 2026-
LACOB JOSEPHMMay 20, 2026-
LACOB JOSEPHAMay 20, 2026-
Vitalone Britt J.MMay 20, 2026-
Vitalone Britt J.MMay 20, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$4.0B$4.0B
Gross Profit-$2.8B$2.7B
Operating Income-$607.6M$545.8M
Net Income-$421.4M$410.4M
Gross Margin-70.0%67.2%
Op. Margin-15.2%13.5%
Net Margin-10.5%10.2%
Balance Sheet
Total Assets$6.1B$6.2B$6.2B
Equity-$3.9B$4.0B
ROE-10.9%10.1%
Per Share
EPS-$5.62$5.65
Cash Flow
Operating CF-$738.2M$593.2M
CapEx$177.7M$115.6M$102.4M

Source: XBRL data in Align Technology (ALGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$3.75B
Q2 202638$5.16B
Q1 202637$4.66B
Q4 202535$4.23B
Q3 202537$3.53B
Q2 202535$5.33B
Q1 202532$3.63B
Q4 202429$4.17B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 279 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 18, 2026Analysis-
8-KNov 6, 2026Analysis-
10-QNov 4, 2026Analysis
8-KOct 28, 2026Analysis-
8-KOct 28, 2026Analysis-
4Aug 31, 2026--
8-KAug 31, 2026Analysis-
SC 13GAug 6, 2026-
10-QAug 5, 2026Analysis
8-KJul 29, 2026Analysis-
8-KJul 29, 2026Analysis-
8-KJul 9, 2026Analysis-
8-KJun 22, 2026Analysis-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
8-KMay 20, 2026Analysis

Related Health Care companies

All Health Care →

ALGN SEC filings: frequently asked questions

Which institutions hold ALGN stock?

As of September 30, 2026, the largest Align Technology (ALGN) holders among the 13F filers tracked by SignalX were BlackRock ($651.5 million), Vanguard Capital Management LLC ($634.6 million), Vanguard Portfolio Management LLC ($451.4 million), Goldman Sachs Group ($401.6 million), State Street Corp ($375.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Align Technology (ALGN) reported revenue of $4.0 billion (up 0.9% from FY2024) and net income of $410.4 million. Diluted EPS was $5.65. The figures come from the XBRL data in the 10-K.

What are the main risks in ALGN's latest 10-K?

In the 10-K filed February 27, 2026, Align Technology (ALGN) flagged: Section 232 investigation by U.S. Dept of Commerce into PPE/medical device imports directly threatens Align's Mexico-manufactured clear aligners shipped to U.S. iTero HQ in Israel near Hamas conflict zone; Mexico manufacturing exposed to drug cartel/gang activity disrupting production and logistics. (AI summary of the Risk Factors section.)

What did ALGN report in its latest 8-K?

Align Technology (ALGN) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Board expands from 11 to 13 directors, adding Paul Clancy immediately and Ian Bell effective December 10, 2026.

What are the latest ALGN SEC filings?

Align Technology (ALGN) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 19, 2026.

What is ALGN's SEC CIK number?

Align Technology (ALGN)'s SEC Central Index Key (CIK) is 1097149. EDGAR lists every ALGN filing under that number.

Ask anything about ALGN

The research agent reads ALGN's filings, financials, insider trades and 13F holders, then answers with sources.